Drug Profile
RP 517
Alternative Names: 99Tcm-RP517; RP517; Technetium-99m-RP517Latest Information Update: 25 Nov 2005
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer AnorMED; Bristol-Myers Squibb
- Class Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 Nov 2005 Discontinued - Phase-I for Solid tumour diagnosis in USA (unspecified route)
- 24 Mar 2000 Phase-I clinical trials for Solid tumour diagnosis in USA (unspecified route)
- 09 Sep 1998 Preclinical development for Inflammation diagnosis in USA (unspecified route)